Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes

22Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.

Abstract

Introduction The diagnostic utility of in vivo amyloid β (Aβ) imaging to aid in the clinical distinction between frontotemporal dementia (FTD) and Alzheimer's disease remains unclear without data on the prevalence and severity of Aβ in pathologically confirmed FTD syndromes. Methods Aβ was assessed in 98 autopsy-confirmed FTD and 36 control cases, and the pathological accuracy of 11C-Pittsburgh compound B (PiB)–positron emission tomography imaging was assessed in a subset of FTD cases (n = 15). Results Aβ was identified in a similar proportion of FTD syndromes and age-matched controls and increases with age. Alzheimer's disease pathology was identified in all cases with high PiB retention and in one case with low PiB retention. We further demonstrate a strong regional correlation between volume fraction of histological Aβ with PiB standard uptake value ratio scaled to the white matter. Discussion The present study provides a pathologic reference to assist in the interpretation of in vivo assessments in FTD syndromes.

Cite

CITATION STYLE

APA

Tan, R. H., Kril, J. J., Yang, Y., Tom, N., Hodges, J. R., Villemagne, V. L., … Halliday, G. M. (2017). Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes. Alzheimer’s and Dementia: Diagnosis, Assessment and Disease Monitoring, 9, 10–20. https://doi.org/10.1016/j.dadm.2017.05.005

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free